Deleted Tweets From Scott Gottlieb, R-D.C.

The Monitoring the Future Survey confirms the epidemic use of e-cigs by kids that #FDA first identified in September and took action to reverse in November by limiting the access and appeal of these products to children; by targeting the role of flavors. https://t.co/qaGmKJHXVp

This new survey confirms data from the National Youth Tobacco Survey and affirms what we’ve known - that youth use of e-cigarettes is at an epidemic proportion. This is why #FDA has taken new steps to curtail the access and appeal of these products to kids https://t.co/x5bjMer6Xx

New technology such as genomic interrogation of human and food samples are enabling us to better identify outbreaks. The tools for doing more effective track and trace to isolate contaminated products and implement more targeted recalls need to catch up https://t.co/L617dxvqso

RT @US_FDA: We continue to focus on approving high-quality, lower cost, safe & effective generics. On the heels of the Oct. rec… https://t.co/2zDXJWi8SU

RT @HHSGov: The opioid epidemic is one of HHS's top priorities. @SecAzar explains how the Department is working to combat the c… https://t.co/S7np2gBZtW

#FDA’s new guidance is aimed at applying modern and efficient oncology trial designs, as well as explore novel endpoints, such as minimal residual disease. https://t.co/SO7b5PKZRQ

RT @DepSecHargan: On behalf of @SecAzar, thanks to our scientific & public health experts at @HHSGov who worked w/ our partners @EPA… https://t.co/jfZ8hcBsLk

RT @US_FDA: Congratulations to these three FDA executive leaders on their recognition by the @WhiteHouse! https://t.co/YcOQ5wuILp QT @SGottliebFDA: We're honored that three #FDA Executives were recognized by @WhiteHouse with 2018 Executive Presidential Rank Award… https://t.co/dO1QOOosHM)

RT @tmprowell: Hot off the press! New #FDAOncology Guidance on design of #ClinicalTrials & endpoints to support approval of… https://t.co/Dj53HSmX9L

The letters to the 20 firms stated that it has come to our attention that they appear to be engaging in activities that are subject to regulatory requirements.

#Essure will no longer be sold in U.S. after Dec.31, but #FDA will continue to evaluate product’s long-term safety profile. I’m providing important updates on those efforts. https://t.co/ts3JrE7DBq

#FDA taking new steps to revise and strengthen manufacturer’s postmarket study, to ensure we collect long-term safety information on #Essure; the study will now follow women for five years instead of three: https://t.co/ts3JrE7DBq

RT @ArthurCaplan: Infections put 12 people in hospitals after they received unapproved stem cell products @CNN https://t.co/Tdjnhq1aQR

Following Essure’s removal from the market, the FDA will continue to monitor women with device; we’re working to implement surveillance system and registries to answer crucial questions on devices for women’s health. https://t.co/ts3JrE7DBq

RT @SGottliebFDA: #FDA taking new steps to revise and strengthen manufacturer’s postmarket study, to ensure we collect long-term safe… https://t.co/ElNVbFujwl

RT @SGottliebFDA: Following Essure’s removal from the market, the FDA will continue to monitor women with device; we’re working to im… https://t.co/KffFZaFlP4

RT @NBCNewsHealth: FDA warns some antibiotics can cause serious heart damage https://t.co/geAusAL5QX

RT @DrNancyM_CDC: As of December 14, 2018, more than 166 million doses of #flu vaccine had already been distributed in the U.S. This… https://t.co/oQKZtfy2Ps

RT @FDAanimalhealth: Wishing you happy howlidays from FDA's Center for Veterinary Medicine. https://t.co/OEhjEsdzqY

One of our core missions is to protect the U.S. blood supply; one of the world’s safest. That’s due in part to dedicated #FDA staff who monitor and quickly respond to any potential threats. Thanks to those working through the shutdown to uphold our gold standard of blood safety. https://t.co/pUbDIG67Lj

The Monitoring the Future Survey confirms the epidemic use of e-cigs by kids that #FDA first identified in September and took action to reverse in November by limiting the access and appeal of these products to children; by targeting the role of flavors. https://t.co/qaGmKJHXVp

This new survey confirms data from the National Youth Tobacco Survey and affirms what we’ve known - that youth use of e-cigarettes is at an epidemic proportion. This is why #FDA has taken new steps to curtail the access and appeal of these products to kids https://t.co/x5bjMer6Xx

New technology such as genomic interrogation of human and food samples are enabling us to better identify outbreaks. The tools for doing more effective track and trace to isolate contaminated products and implement more targeted recalls need to catch up https://t.co/L617dxvqso

RT @US_FDA: We continue to focus on approving high-quality, lower cost, safe & effective generics. On the heels of the Oct. rec… https://t.co/2zDXJWi8SU

RT @HHSGov: The opioid epidemic is one of HHS's top priorities. @SecAzar explains how the Department is working to combat the c… https://t.co/S7np2gBZtW

#FDA’s new guidance is aimed at applying modern and efficient oncology trial designs, as well as explore novel endpoints, such as minimal residual disease. https://t.co/SO7b5PKZRQ

RT @DepSecHargan: On behalf of @SecAzar, thanks to our scientific & public health experts at @HHSGov who worked w/ our partners @EPA… https://t.co/jfZ8hcBsLk

RT @US_FDA: Congratulations to these three FDA executive leaders on their recognition by the @WhiteHouse! https://t.co/YcOQ5wuILp QT @SGottliebFDA: We're honored that three #FDA Executives were recognized by @WhiteHouse with 2018 Executive Presidential Rank Award… https://t.co/dO1QOOosHM)

RT @tmprowell: Hot off the press! New #FDAOncology Guidance on design of #ClinicalTrials & endpoints to support approval of… https://t.co/Dj53HSmX9L

The letters to the 20 firms stated that it has come to our attention that they appear to be engaging in activities that are subject to regulatory requirements.

#Essure will no longer be sold in U.S. after Dec.31, but #FDA will continue to evaluate product’s long-term safety profile. I’m providing important updates on those efforts. https://t.co/ts3JrE7DBq

#FDA taking new steps to revise and strengthen manufacturer’s postmarket study, to ensure we collect long-term safety information on #Essure; the study will now follow women for five years instead of three: https://t.co/ts3JrE7DBq

RT @ArthurCaplan: Infections put 12 people in hospitals after they received unapproved stem cell products @CNN https://t.co/Tdjnhq1aQR

Following Essure’s removal from the market, the FDA will continue to monitor women with device; we’re working to implement surveillance system and registries to answer crucial questions on devices for women’s health. https://t.co/ts3JrE7DBq

RT @SGottliebFDA: #FDA taking new steps to revise and strengthen manufacturer’s postmarket study, to ensure we collect long-term safe… https://t.co/ElNVbFujwl

RT @SGottliebFDA: Following Essure’s removal from the market, the FDA will continue to monitor women with device; we’re working to im… https://t.co/KffFZaFlP4

RT @NBCNewsHealth: FDA warns some antibiotics can cause serious heart damage https://t.co/geAusAL5QX

RT @DrNancyM_CDC: As of December 14, 2018, more than 166 million doses of #flu vaccine had already been distributed in the U.S. This… https://t.co/oQKZtfy2Ps

RT @FDAanimalhealth: Wishing you happy howlidays from FDA's Center for Veterinary Medicine. https://t.co/OEhjEsdzqY

One of our core missions is to protect the U.S. blood supply; one of the world’s safest. That’s due in part to dedicated #FDA staff who monitor and quickly respond to any potential threats. Thanks to those working through the shutdown to uphold our gold standard of blood safety. https://t.co/pUbDIG67Lj